Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Nirsevimab, Season 2
MMWR recomm. rep
; 72(34): 1-4, 20230825. tab
Artículo
en Inglés
| BIGG - guías GRADE
| ID: biblio-1512312
Biblioteca responsable:
BR1.1
ABSTRACT
A Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) review of the evidence for benefits and harms for the long-acting monoclonal antibody nirsevimab, (Beyfortus, Sanofi and AstraZeneca) for prevention of respiratory syncytial virus (RSV))-associated lower respiratory tract infection (LRTI) in children <24 months who are at increased risk of severe disease entering their second RSV season was presented to the Advisory Committee on Immunization Practices (ACIP) on February 23, 2023. GRADE evidence type indicates the certainty in estimates from the available body of evidence. Evidence certainty ranges from high certainty to very low certainty
C - All Rights Reserved
Asunto(s)
Texto completo:
Disponible
Colección:
Bases de datos temática
Base de datos:
BIGG - guías GRADE
Asunto principal:
Virus Sincitiales Respiratorios
/
Anticuerpos Monoclonales
Idioma:
Inglés
Revista:
MMWR recomm. rep
Año:
2023
Tipo del documento:
Artículo